MARTINSRIED / MUNCHEN, GERMANY--(Marketwire - October 07, 2010) -
MorphoSys AG /
MorphoSys Announces Acquisition of Sloning
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Combination of Technologies Set to Increase Success Rates in
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
acquisition of the private German company Sloning BioTechnology
biotechnology company developing new methods of synthetic biology.
transaction will make MorphoSys the sole source of Sloning's state-of-
Slonomics technology, which dramatically improves the assembly and
protein libraries. By integrating Slonomics into its existing
technology platform, MorphoSys expects to improve the generation of
candidates such that one in every two projects started reaches
development. The technology will also be used to accelerate the
both therapeutic and diagnostic antibodies. Sloning's shareholders
one-off EUR 19 million cash payment upon signing.
"This acquisition secures our position at the forefront of antibody
commented Dr Simon Moroney, Chief Executive Officer of MorphoSys AG.
unique technology is the most powerful method available for assembling
libraries and has been proven to deliver superior products for a
applications. We plan to use it to generate optimized antibodies much
than can be done today and also to gain access to antibodies that simply
be made with current technologies."
Sloning's patented core technology enables the precise construction of
libraries comprising defined mixtures of amino acids at pre-determined
with unprecedented speed. This technology opens the way to a new and
approach to generating optimized proteins, such as antibodies.
"Current antibody generation technologies use an initial repertoire,
largely determines the properties of the resulting antibody. We intend
Slonomics as the basis of a fundamentally different approach, which will
test multiple generations of antibodies, equivalent to screening many
of molecules, to isolate the best possible candidate", stated Dr Marlies
Chief Scientific Officer of MorphoSys AG. "We expect to shorten the time
to generate an antibody drug candidate by a third and even more
increase the proportion of programs reaching clinical development to 50%."
Sloning, founded in 2001, is a private company based in Puchheim, near
The major shareholders are HBM BioVentures, KfW, LBBW Venture
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft. The company
developed and refined its proprietary technologies through collaborations
number of pharmaceutical and industrial customers.
"We believe that the two companies' technology portfolios and
expertise will lead to superior therapeutic, diagnostic and
products," commented the Chief Executive Officer of Sloning, Dr Heinz
who will join MorphoSys, becoming a member of the senior management team.
"MorphoSys has the financial resources required to fully exploit the
and capabilities of the Sloning technology platform and there is a strong
the culture of both companies," complements Dr Harald Poth,
Sloning's advisory board.
Sloning's financial results will be fully consolidated into MorphoSys's
from today onwards. Today's transaction is not material in
MorphoSys's financial guidance for 2010.
MorphoSys will hold a public conference call tomorrow, October 08, at 02:00
CEST (08:00 a.m. EDT, 01:00 p.m. BST) to present key information
acquisition of Sloning.
Dial-in number for the Conference Call (listen-only):
Germany: +49 (0) 89 24443 2975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 212 999 6659
Please dial in 10 minutes before the beginning of the conference.
In addition, MorphoSys offers participants the opportunity to follow the
presentation through a simultaneous slide presentation online
A live webcast, slides, webcast replay and transcript will be made
Approximately two hours after the press conference, a slide-synchronized
replay of the conference will be available onhttp://www.morphosys.com
+++ Save the dates: MorphoSys's R&D Day 2010 +++
London - Thursday, November 25, 2010
New York - Monday, November 29, 2010 ??
MorphoSys is an independent biotechnology company that develops novel
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical
MorphoSys has created a pipeline of more than 60 drug candidates. The
expanding its drug pipeline by adding new partnered programs, and by
portfolio of fully-owned therapeutic antibodies. For its proprietary
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is
in Munich, Germany and listed on the Frankfurt Stock Exchange under the
"MOR". For further information, visithttp://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and
RapMAT® are registered
trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
--- End of Message ---
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE